anti-inflammatoty and immuno-therapy for COVID-19: living meta-analysis of clinical studies

Table Graph

anti-inflammatoty and immuno-therapy - versus potential COVID-19 treatments - for COVID 19 hospitalized pdf xlsx method abbreviations

Outcome	Relative effect 95%CI	Trt. better when	I2	k (RCT/OBS)	Bayesian probability	Overall ROB	Publication bias	Degree of certainty	Endpoint importance	Published MA
efficacy endpoints 00
death D28	0.91 [0.86, 0.96]	< 1	20%	69 studies (82/-)	100.0 %	some concern	critical	moderate	crucial	-
death or transfer to ICU	0.79 [0.50, 1.24]	< 1	0%	2 studies (5/-)	84.9 %	some concern	not evaluable	moderate	crucial	-
deaths	0.89 [0.85, 0.93]	< 1	20%	114 studies (139/-)	100.0 %	some concern	critical	moderate	crucial	1
deaths (time to event analysis only)	0.84 [0.72, 0.98]	< 1	31%	20 studies (26/-)	98.8 %	some concern	low	moderate	crucial	-
clinical deterioration	0.70 [0.57, 0.86]	< 1	48%	26 studies (29/-)	100.0 %	some concern	low	moderate	important	-
clinical improvement	1.17 [1.08, 1.27]	> 1	37%	34 studies (39/-)	100.0 %	some concern	critical	moderate	important	-
clinical improvement (14-day)	1.40 [1.12, 1.74]	> 1	45%	11 studies (14/-)	99.9 %	low	critical	high	important	-
clinical improvement (21-day)	1.50 [0.22, 10.08]	> 1	0%	1 study (1/-)	66.1 %	NA	not evaluable		important	-
clinical improvement (28-day)	1.59 [1.14, 2.21]	> 1	48%	12 studies (12/-)	99.7 %	some concern	critical	moderate	important	-
clinical improvement (7-day)	1.32 [0.90, 1.96]	> 1	47%	7 studies (7/-)	92.0 %	some concern	not evaluable	moderate	important	-
clinical improvement (time to event analysis only)	1.14 [1.04, 1.25]	> 1	22%	18 studies (20/-)	99.8 %	some concern	critical	moderate	important	-
death or ventilation	0.90 [0.86, 0.96]	< 1	52%	27 studies (30/-)	100.0 %	some concern	critical	moderate	important	-
hospital discharge	1.06 [1.00, 1.13]	> 1	57%	14 studies (17/-)	97.1 %	some concern	low	moderate	important	-
hospitalization	1.00 [0.14, 7.34]	< 1	0%	1 study (1/-)	50.0 %	NA	not evaluable		important	-
mechanical ventilation	0.86 [0.78, 0.95]	< 1	22%	34 studies (37/-)	99.9 %	some concern	critical	moderate	important	1
mechanical ventilation (time to event analysis only)	0.97 [0.62, 1.52]	< 1	0%	2 studies (2/-)	55.5 %	some concern	not evaluable	moderate	important	-
radiologic improvement (14-day)	3.18 [1.91, 5.29]	> 1	0%	4 studies (4/-)	100.0 %	some concern	not evaluable	moderate	important	-
Recovery (time to event analysis only)	1.02 [0.81, 1.28]	> 1	0%	1 study (1/-)	56.7 %	NA	not evaluable		important	-
viral clearance	2.53 [1.31, 4.90]	> 1	80%	10 studies (11/-)	99.7 %	some concern	low	moderate	important	-
viral clearance (time to event analysis only)	1.33 [0.77, 2.30]	> 1	77%	3 studies (4/-)	84.9 %	some concern	not evaluable	moderate	important	-
viral clearance by day 14	1.15 [0.15, 9.03]	> 1	97%	6 studies (7/-)	55.3 %	some concern	not evaluable	moderate	important	-
viral clearance by day 7	1.75 [1.04, 2.96]	> 1	63%	7 studies (9/-)	98.2 %	some concern	serious	moderate	important	-
ICU admission	0.76 [0.60, 0.96]	< 1	0%	13 studies (16/-)	98.9 %	some concern	low	moderate	non important	-
off oxygenation	1.65 [0.05, 50.02]	> 1	81%	2 studies (2/-)	61.1 %	high	not evaluable	low	non important	-
recovery	1.17 [0.98, 1.39]	> 1	25%	7 studies (7/-)	96.2 %	low	not evaluable	high	non important	-
safety endpoints 00
composite safety outcome	1.56 [0.78, 3.11]	< 1	0%	1 study (1/-)	10.3 %	NA	not evaluable		important	-
related AE (TRAE)	1.26 [0.14, 11.07]	< 1	0%	2 studies (2/-)	41.9 %	some concern	not evaluable	moderate	important	-
related SAE (TRSAE)	2.04 [0.07, 63.93]	< 1	0%	1 study (1/-)	34.4 %	NA	not evaluable		important	-
serious adverse events	1.03 [0.89, 1.20]	< 1	23%	26 studies (29/-)	33.8 %	some concern	low	moderate	important	-
superinfection	0.70 [0.46, 1.07]	< 1	53%	4 studies (5/-)	95.0 %	low	not evaluable	high	important	-
acute kidney injury	0.43 [0.14, 1.34]	< 1	0%	1 study (-/1)	92.7 %	NA	not evaluable		non important	-
adverse events	1.26 [1.04, 1.51]	< 1	20%	22 studies (24/-)	0.9 %	some concern	low	moderate	non important	-
arrhythmia	0.16 [0.03, 0.90]	< 1	0%	1 study (-/1)	98.1 %	NA	not evaluable		non important	-
cardiovascular or renal events	1.87 [1.25, 2.80]	< 1	0%	1 study (-/1)	0.1 %	NA	not evaluable		non important	-
elevated liver enzymes	0.52 [0.18, 1.51]	< 1	0%	1 study (-/1)	88.5 %	NA	not evaluable		non important	-
Myocardial infarction	0.87 [0.19, 3.92]	< 1	0%	1 study (-/1)	57.2 %	NA	not evaluable		non important	-
venous thromboembolism	5.23 [0.42, 65.62]	< 1	0%	1 study (-/1)	10.2 %	NA	not evaluable		non important	-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.

anti-inflammatoty and immuno-therapy - versus potential COVID-19 treatments - for COVID 19 hospitalized pdf xlsx method abbreviations

efficacy endpoints 00

safety endpoints 00